Fotemustine

Fotemustine

Clinical data
Trade names	Mustophoran
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: D
ATC code	L01AD05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)
Identifiers
IUPAC name (RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino} ethyl)phosphonate
CAS Number	92118-27-9 N
PubChem CID	104799
DrugBank	DB04106 N
ChemSpider	94600 Y
UNII	GQ7JL9P5I2
KEGG	D07255 Y
ChEMBL	ChEMBL549386 Y
CompTox Dashboard (EPA)	DTXSID80869091
ECHA InfoCard	100.158.792
Chemical and physical data
Formula	C9H19ClN3O5P
Molar mass	315.69 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=P(OCC)(OCC)C(NC(=O)N(N=O)CCCl)C
InChI InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14) Y Key:YAKWPXVTIGTRJH-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA.¹ A study² has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).